25 results about "Resistant mutants" patented technology

The invention relates to preparation and application of diarylamine compounds containing a propionamido indole structure. The compounds have a structural formula as shown in a general formula (I). The invention relates to a compound shown in a general formula (I), which has a strong effect of inhibiting L858R / T790M / C797S and Del19 / T790M / C797S drug-resistant mutant EGFR kinase, and also relates to application of the compound and pharmaceutically acceptable salt thereof in preparation of drugs for treating and / or preventing diseases caused by drug-resistant mutation of EGFR kinase, the invention particularly relates to application in preparation of medicines for treating and / or preventing cancers. The invention also provides a preparation method of the compounds, a pharmaceutical composition containing the compounds and application of the pharmaceutical composition. The compound is especially used for preparing drugs for treating and / or preventing lung cancer, and has good antitumor drug development and application prospects. (I)

The invention relates to diarylamine compounds containing a dimethyl phosphine oxide structure as well as a preparation method and application of the diarylamine compounds. The compounds have a structural formula as shown in a general formula (I). The invention relates to a compound shown in a general formula (I), which has a strong effect of inhibiting L858R / T790M / C797S drug-resistant mutant EGFR kinase, and also relates to application of the compound and pharmaceutically acceptable salt thereof in preparation of drugs for treating and / or preventing diseases caused by drug-resistant mutation of EGFR kinase, the invention particularly relates to application in preparation of medicines for treating and / or preventing cancers. The invention also provides a preparation method of the compounds, a pharmaceutical composition containing the compounds and application of the pharmaceutical composition. The compound is especially used for preparing drugs for treating and / or preventing lung cancer, and has good antitumor drug development and application prospects.

The invention relates to a corn WRKY transcription factor ZmWRKY74 as well as a coding gene and application thereof, and belongs to the technical field of plant gene breeding, the CDS sequence of the coding gene of the transcription factor ZmWRKY74 is as shown in SEQ ID NO.1, the gene negatively regulates the drought tolerance of crop plants, and the amino acid sequence of the transcription factor ZmWRKY74 is as shown in SEQ ID NO.3. Gene positioning analysis is carried out on a drought-resistant mutant of corn, it is found that the ZmWRKY74 gene is an effect gene capable of improving the tolerance of corn to drought stress, and through a ZmWRKY74 gene overexpression experiment, the negative regulation effect of the ZmWRKY74 gene on the drought tolerance of corn plants is verified; important theoretical significance and application value are provided for creation of new corn germplasm and molecular breeding of corn.

The invention discloses a novel application of a pyrrolone benzenesulfonamide compound, the compound has obvious antiviral activity and low cytotoxicity, can be used as an allosteric inhibitor of coronavirus 3CL protease (3CLpro), and especially shows efficient inhibition capability on SARS-CoV-2 3CLpro. An enzyme activity test and molecular dynamics simulation result shows that the compound is combined with a 3CLpro allosteric site to induce the volume of a catalytic pocket to shrink, so that enzyme activity inhibition is realized, and the drug resistance risk caused by active site mutation is avoided. In-vitro antiviral experiments further show that the compound has a strong inhibition effect on SARS-CoV-2 wild type and various drug-resistant mutant strains (such as E166V and S144M), the EC50 value is as low as the nanomole level, the selection index is high, and the safety is good. Besides, based on the high conservative property of 3CLpro in different coronaviruses, the compound provided by the invention also shows inhibitory activity on other coronaviruses 3CLpro such as SARS-CoV, MERS-CoV and the like, and has broad-spectrum antiviral potential. The compound can be used for preparing medicines for preventing, relieving or treating related diseases caused by coronavirus infection, and has a good clinical application prospect.

The application belongs to the field of genetic engineering and medical engineering, and discloses virK Application of gene in regulation of Klebsiella pneumoniae virulence. The application finds that the expression level of the gene is significantly increased in polymyxin-resistant mutant strains through transcriptome analysis, virK Further research shows that the expression of the gene is regulated by the PhoP / PhoQ two-component regulatory system. The application constructs virK Gene deletion mutant strains and complementary strains, and compares the virulence difference of the strains in an animal infection model, finds that virK The virulence of the deletion strain is significantly reduced, and the complementary strain can restore the virulence phenotype, indicating that virK The gene plays an important role in the regulation of Klebsiella pneumoniae virulence. The application first finds that PhoP can regulate virK Gene expression, and affects the virulence phenotype of Klebsiella pneumoniae through the regulation pathway, thereby revealing a new virulence regulation mechanism, and providing a theoretical basis for subsequent targeted intervention.

The invention discloses an acid-resistant cyclodextrin glycosyl transferase (CGTS) mutant and an application of the acid-resistant cyclodextrin glycosyl transferase CGTase mutant. The acid-resistant cyclodextrin glycosyl transferase CGTase mutant has the advantages that the acid-resistant cyclodextrin glycosyl transferase CGTase mutant can be used as an acid-resistant mutant; the CGTase is subjected to multi-site directed mutation based on an artificially designed wild type sequence (the amino acid sequence is as shown in SEQ ID NO: 2), and an acid-resistant mutant (the amino acid sequence is as shown in SEQ ID NO: 16) with the optimal reaction pH of 5.0 is obtained. The mutant can maintain more than 80% of catalytic activity in a pH range of 4.0-5.5, and can be stabilized for 10 hours under a strong acid condition (pH is 4.0). Compared with a wild type, the mutant has a higher conversion rate, a shorter reaction period and better substrate stability in the process of synthesizing 2-O-alpha-D-glucopyranosyl-L-ascorbic acid (AA-2G), the industrial production efficiency of the AA-2G can be remarkably improved, and the mutant has an important application value.

The application discloses application of SGI-7079 in treating FLT3 mutant acute myeloid leukemia. The application research shows that SGI-7079 can be stably combined with FLT3, inhibit the phosphorylation level of FLT3 and downstream STAT5, AKT and ERK, and induce G1 phase arrest and cell apoptosis. In vitro, SGI-7079 has strong inhibitory effect on FLT3-ITD and drug-resistant mutant cells; in a FLT3-ITD mouse model, SGI-7079 can significantly reduce leukemia load and prolong survival, and shows better curative effect than existing drugs on drug-resistant mutations such as F691L and D835Y. Meanwhile, SGI-7079 also has significant inhibitory effect on primary cells of FLT3-ITD positive patients. It is shown that SGI-7079 can be used as a new drug candidate for treating FLT3 mutation and drug-resistant AML, and provides a new direction for optimizing targeted therapy strategy.

This invention belongs to the field of rice molecular breeding technology and discloses genes regulating cold and salt tolerance in rice seedlings. SOP17 Its applications. This gene has the nucleotide sequence shown in SEQ ID NO.1, and the amino acid sequence of the protein it encodes is shown in SEQ ID NO.2. This invention obtained a seedling-stage cold-resistant mutant of indica rice 9311 through EMS mutagenesis. sop17-1 The clone was obtained by analyzing the Mutmap. SOP17 Genes. Constructed using CRISPR / Cas9 gene editing technology. SOP17 Gene knockout vector, to obtain SOP17 Homozygous mutant lines. Functional validation showed that... SOP17 SOP17 This gene simultaneously negatively regulates cold and salt tolerance in rice seedlings. Knocking out this gene significantly enhances the tolerance of rice seedlings to low temperature (8°C) and salt (150mM NaCl). This invention provides new gene resources and molecular targets for breeding stress-resistant rice varieties.

The invention provides a pharmaceutical composition for degrading a PML-RAR alpha protein drug-resistant mutant and application of the pharmaceutical composition. The pharmaceutical composition comprises interferon and arsenic trioxide. According to the composition disclosed by the invention, HeLa cells or NB4 cells for expressing the drug-resistant mutant of the PML-RAR alpha fusion protein are jointly treated by using interferon and arsenic trioxide, so that the degradation of the drug-resistant mutant of the PML-RAR alpha fusion protein is specifically induced. The invention provides help for researching the degradation mechanism of the PML-RAR alpha fusion protein drug-resistant mutant and developing drugs for patients with arsenic drug-resistant APL.

This invention relates to the fields of enzyme engineering and bioengineering, and particularly to the bioengineering technology of an MHET hydrolase. This invention discloses a mutant MHET hydrolase, wherein the amino acid at position 66 of IsMHETase is mutated from Ala to Pro, amino acid at position 136 from Ser to Glu, amino acid at position 159 from Thr to Val, amino acid at position 192 from Met to Phe, amino acid at position 330 from Ala to Lys, amino acid at position 333 from Ala to Arg, amino acid at position 328 from Thr to Arg, amino acid at position 410 from Gln to Phe, amino acid at position 413 from Ser to Asn, amino acid at position 434 from Asp to Thr, amino acid at position 501 from Ala to Ile, amino acid at position 509 from Ala to Lys, and amino acid at position 561 from Ser to Val; the amino acid composition of the MHET hydrolase IsMHETase is shown in SEQ ID No. 1 of the sequence listing. Compared with wild-type MHET hydrolase, the heat-resistant mutant provided by this invention can be used in combination with PET hydrolase at higher temperatures, and its PET degradation activity is significantly improved.

This invention discloses a method and its application for creating stress-resistant mutants of common bean using chemical mutagenesis. The main steps include: determining the screening concentration of hydroxyproline (Hyp), determining the median lethal dose of ethyl methanesulfonate (EMS), and subculturing the stress-resistant mutants. After 3-5 subcultures, the stress-resistant mutants screened by this invention ultimately yielded 31 cotyledonary nodes of common bean resistant to hydroxyproline (Hyp), with a mutation rate of 8.16%. This invention can induce mutagenesis and directionally screen for stress-resistant common bean mutants, providing material support for stress-resistant breeding of common bean.

The invention provides a rice OsACC herbicide-resistant mutant gene double-marker rapid detection method and a kit, and belongs to the technical field of resistance analysis. The invention provides a double-labeled primer group which is used for detecting 11672nd base mutation in a coding sequence of a 34th exon CT structural domain (1653bp) of a rice OsACC gene, the mutation can endow a plant with ACCase inhibitor herbicide resistance, the invention specifically discloses a targeting fragment on the gene, a wild type fragment comprises a sequence as shown in SEQ ID No.1, the wild type fragment comprises a sequence as shown in SEQ ID No.2, and the wild type fragment comprises a sequence as shown in SEQ ID No.3 and a sequence as shown in SEQ ID No.4. The mutant fragment comprises a sequence as shown in SEQ ID No. 2. The invention constructs a dual molecular marker detection system, can solve the problem of low resolution or strong equipment dependence of single molecular marker type detection, has the advantages of high throughput, low cost and high accuracy, and provides a basis for herbicide resistance identification and precise herbicide selection prevention and control of resistant weeds.

The invention discloses a directional improvement method for wheat basal stem rot resistance, and belongs to the technical field of wheat breeding. According to the invention, molecular marker-assisted selection is combined, three wheat materials carrying disease-resistant sites are screened from a natural population, mutants are created through EMS mutagenesis, and a batch of disease-resistant mutant materials are obtained by combining a rapid generation adding and identification method. According to the invention, a material carrying a single disease-resistant site is subjected to genetic improvement, so that the aim of directionally improving the basal stem rot resistance of the wheat is achieved, the problems of scarcity of resistance resources, long breeding period and the like are solved, and an important basis and key technical support are provided for genetic research and breeding research of basal stem rot resistance of the wheat.

Inhibitors of wild-type RET and resistant mutant variants thereof, pharmaceutical compositions comprising such compounds and methods of using such compounds and compositions.

The invention relates to tri-substituted anisole compounds containing an N-propyl alcohol indole structure as well as a preparation method and application of the tri-substituted anisole compounds. The compounds have a structural formula as shown in a general formula (I). The invention relates to a compound shown in a general formula (I), which has a strong effect of inhibiting L858R / T790M / C797S and Del19 / T790M / C797S drug-resistant mutant EGFR kinase, and also relates to application of the compound and pharmaceutically acceptable salt thereof in preparation of drugs for treating and / or preventing diseases caused by drug-resistant mutation of EGFR kinase, the invention particularly relates to application in preparation of medicines for treating and / or preventing cancers. The invention also provides a preparation method of the compounds, a pharmaceutical composition containing the compounds and application of the pharmaceutical composition. The compound is especially used for preparing drugs for treating and / or preventing lung cancer, and has good antitumor drug development and application prospects. (I)

The invention discloses a heat-resistant mutant of protein glutaminase (PG enzyme) as well as a construction method and application of the heat-resistant mutant, and belongs to the technical field of protein engineering. The amino acid sequence of the PG enzyme is obtained by performing multi-sequence comparison on the PG enzyme from C. proteolyticum YF810 and other PG enzymes which are from different strains and have improved heat resistance, screening heat-resistant single-point mutations, and performing combined mutation on two or more of all beneficial single-point mutations to obtain a combined mutant of the PG enzyme. According to the five-combination mutant of the PG enzyme with the heat resistance improved to the maximum degree, the T5010min value is improved by 12.80 DEG C, the t1 / 260 DEG C value is improved by 55.13 times, and compared with wild type PG enzyme, the enzyme activity is not reduced. Therefore, compared with the wild type PG enzyme, the mutant of the PG enzyme provided by the invention has better heat resistance and better industrial application prospect.

The invention discloses an acid-resistant mutant of candida antarctica lipase A and application of the acid-resistant mutant. In order to solve the problem that the Candida antarctica lipase A is easy to inactivate in an acid environment, the acid-resistant mutant of the Candida antarctica lipase A is obtained by mutating the 45th or 161th amino acid of the Candida antarctica lipase A. Compared with candida antarctica lipase A, the acid-resistant mutant has the advantages that the optimum reaction temperature, pH and specific activity of the acid-resistant mutant are not obviously changed, but the residual enzyme activity of the acid-resistant mutant is obviously improved after the acid-resistant mutant is incubated for the same time in an acid environment and is improved by 10-26%, and the yield of biodiesel prepared by catalyzing acid oil within the same time is also obviously improved. The mutant disclosed by the invention can be used for preparing biodiesel under an acidic condition, and is beneficial to recycling of acid oil.

The application discloses application of SGI-7079 in treating FLT3 mutant acute myeloid leukemia. The application research shows that SGI-7079 can be stably combined with FLT3, inhibit the phosphorylation level of FLT3 and downstream STAT5, AKT and ERK, and induce G1 phase arrest and cell apoptosis. In vitro, SGI-7079 has strong inhibitory effect on FLT3-ITD and drug-resistant mutant cells; in a FLT3-ITD mouse model, SGI-7079 can significantly reduce leukemia load and prolong survival, and shows better curative effect than existing drugs on drug-resistant mutations such as F691L and D835Y. Meanwhile, SGI-7079 also has significant inhibitory effect on primary cells of FLT3-ITD positive patients. It is shown that SGI-7079 can be used as a new drug candidate for treating FLT3 mutation and drug-resistant AML, and provides a new direction for optimizing targeted therapy strategy.

Provided are a cyclic 2-aminopyrimidine compound having a structure as shown in formula (I), or a pharmaceutically acceptable salt, stereoisomer or prodrug molecule thereof, and a use thereof. The compound can effectively inhibit the activity of EGFR protein kinase drug-resistant mutants (such as EGFRT790M and EGFR19del / T790M / C797S), and can overcome the clinical drug resistance of patients suffering from tumors such as non-small cell lung cancer induced by existing third-generation selective EGFRT790M small molecule inhibitors Osimertinib (AZD9291), Olmutinib (HM6171), Rociletinib (CO-1686) and the like.

The invention discloses a herbicide-resistant mutant of an AhALS2 gene and application of the herbicide-resistant mutant in peanut breeding. The mutant is subjected to site-specific mutagenesis on methionine at the 200th site of an amino acid sequence of AhALS2 protein to obtain isoleucine (namely M200I mutation). According to the invention, the herbicide-resistant peanut material with M200I mutation in the AhALS2-B gene and the AhALS2-A gene is respectively obtained by editing the AhALS2-B gene and the AhALS2-A gene. According to the invention, a brand new herbicide resistance site M200 in the peanut AhALS2 gene is successfully excavated and verified by using a base editing technology, and the M200I mutant is accurately created in peanuts by constructing a CBE-M200 editing carrier and has remarkable resistance to imidazolone herbicides. The invention not only provides a new germplasm and a core gene resource for peanut herbicide-resistant breeding, but also provides a new idea for cultivating herbicide-resistant varieties in other crops by using homologous editing.

A protease-resistant ADAMTS13 mutant protein or nucleic acid encoding the ADAMTS13 mutant protein is provided. The ADAMTS13 mutant protein comprises a mammalian ADAMTS13 protein in which one or more protease cleavage sites within the protein are replaced with amino acid sequence that is resistant to protease cleavage, and the mutant protein retains von Willebrand factor (VWF)-cleaving activity. The protease-resistant ADAMTS13 mutant is useful as a thrombolytic agent to treat common thrombotic disorders, including stroke, myocardial infarction, venous thromboembolism, and rare microvascular thrombotic disorders like thrombotic thrombocytopenia purpura (TTP).

The invention relates to the field of bioengineering, in particular to a mutant, a nucleic acid molecule, an expression vector and application thereof. The invention provides a mutant which has one or more amino acid site mutations on the basis of wild type phenylalanine ammonialyase: the 272nd site, the 273rd site, the 411th site, the 412th site, the 413th site, the 415th site, the 500th site, the 507th site and the 511th site, and the amino acid sequence of the wild type phenylalanine ammonialyase is shown as SEQ ID NO: 1. According to the invention, a phenylalanine ammonialyase (PAL) coding gene is identified and represented in details from tobacco (Nicotiana tabacum), and the gene is not systematically researched and represented yet. A series of mutants are constructed through protein engineering research, and several heat-resistant mutants are outstanding in heat-resistant effect and have important significance.

The invention belongs to the field of medicine, and provides a PROTAC compound targeting PI3Kalpha and preparation and application thereof. The PROTAC compound is selected from a compound as shown in a formula (I) or pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof. The compound realizes specific degradation of PI3Kalpha protein instead of pure enzyme activity inhibition by combining an allosteric site of PI3Kalpha and E3 ligase at the same time. The compound still keeps efficient degradation activity on clinically common drug-resistant mutants, and the problem that a traditional small-molecule inhibitor is prone to drug resistance is effectively solved. The structure of the formula (I) is shown in the specification.

This invention relates to the fields of agricultural biotechnology and crop breeding technology, specifically a method for screening drought-resistant rice mutants. The method includes the following steps: using a space-induced mutation SP₂ generation population as material, under stress with 22% PEG-6000 solution, initial drought-resistant germplasm is selected based on germination rate; the initial selected germplasm is cultivated to the three-leaf stage, and under stress with 24% PEG-6000 solution, a second screening is conducted based on chlorophyll content ratio; the malondialdehyde (MDA), proline content, and antioxidant enzyme activity of the selected plants are measured to screen drought-resistant mutants with excellent physiological indicators. This invention utilizes a multi-level progressive screening system—primary phenotypic screening, secondary phenotypic screening, and physiological verification—to achieve efficient and accurate identification of drought-resistant mutants from space-induced mutations, significantly reducing the false positive rate and providing fully validated superior germplasm resources for drought-resistant rice breeding.

The application relates to an ultraviolet-resistant and high-temperature-resistant high-efficiency Beauveria bassiana mutant strain Bb-UV-18 and application thereof. Beauveria bassiana The application obtains a Beauveria bassiana mutant strain Bb-UV-18 through mutagenesis research, and is preserved in the China Guangdong Microbial Digital Museum Center on January 23, 2026, with a preservation number of GDMCC No: 67738. The mutant strain has strong ultraviolet resistance, good high-temperature resistance, and the prevention and treatment effect on sweet potato small elephant beetles, piezodorus guildinii, sweet potato small green tortoise beetles and the like is obviously improved. Moreover, the strain is a mutant strain of a Chinese native wild strain, is more suitable for the natural environment of China, has fast colony growth rate, high spore yield and is beneficial to industrialization, and has important application values in aspects of chemical pesticide substitution, efficient, safe and sustainable prevention and treatment of sweet potato small elephant beetles, piezodorus guildinii, sweet potato small green tortoise beetles and the like.